The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

Graham Cocks; Sarah Curran; Priya Gami; Dafe Uwanogho; Aaron R. Jeffries; Annie Kathuria; Walter Lucchesi; Victoria Wood; Rosemary Dixon; Caroline Ogilvie; Thomas Steckler; Jack Price

doi:10.1007/s00213-013-3196-4

The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

Graham Cocks, Sarah Curran, Priya Gami, Dafe Uwanogho, Aaron R. Jeffries, Annie Kathuria, Walter Lucchesi, Victoria Wood, Rosemary Dixon, Caroline Ogilvie, Thomas Steckler, Jack Price^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

35 Citations (Scopus)

Abstract

Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years.

Original language	English
Pages (from-to)	1079-1088
Number of pages	10
Journal	Psychopharmacology
Volume	231
Issue number	6
DOIs	https://doi.org/10.1007/s00213-013-3196-4
Publication status	Published - Mar 2014

Keywords

Induced pluripotent stem cells
Autism
SHANK3
POSTSYNAPTIC DENSITY PROTEINS
SINGLE POLYCISTRONIC VECTOR
HUMAN IPS CELLS
HUMAN KERATINOCYTES
DELETION SYNDROME
PURKINJE-CELLS
SOMATIC-CELLS
GENERATION
DIFFERENTIATION
EXPRESSION

Access to Document

10.1007/s00213-013-3196-4

Cite this

@article{37498466f40047d19f3af4510c62b8f5,

title = "The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders",

abstract = "Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years.",

keywords = "Induced pluripotent stem cells, Autism, SHANK3, POSTSYNAPTIC DENSITY PROTEINS, SINGLE POLYCISTRONIC VECTOR, HUMAN IPS CELLS, HUMAN KERATINOCYTES, DELETION SYNDROME, PURKINJE-CELLS, SOMATIC-CELLS, GENERATION, DIFFERENTIATION, EXPRESSION",

author = "Graham Cocks and Sarah Curran and Priya Gami and Dafe Uwanogho and Jeffries, {Aaron R.} and Annie Kathuria and Walter Lucchesi and Victoria Wood and Rosemary Dixon and Caroline Ogilvie and Thomas Steckler and Jack Price",

year = "2014",

month = mar,

doi = "10.1007/s00213-013-3196-4",

language = "English",

volume = "231",

pages = "1079--1088",

journal = "Psychopharmacology",

issn = "0033-3158",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

AU - Cocks, Graham

AU - Curran, Sarah

AU - Gami, Priya

AU - Uwanogho, Dafe

AU - Jeffries, Aaron R.

AU - Kathuria, Annie

AU - Lucchesi, Walter

AU - Wood, Victoria

AU - Dixon, Rosemary

AU - Ogilvie, Caroline

AU - Steckler, Thomas

AU - Price, Jack

PY - 2014/3

Y1 - 2014/3

N2 - Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years.

AB - Until now, models of psychiatric diseases have typically been animal models. Whether they were to be used to further understand the pathophysiology of the disorder, or as drug discovery tools, animal models have been the choice of preference in mimicking psychiatric disorders in an experimental setting. While there have been cellular models, they have generally been lacking in validity. This situation is changing with the advent of patient-specific induced pluripotent stem cells (iPSCs). In this article, we give a methodological evaluation of the current state of the iPS technology with reference to our own work in generating patient-specific iPSCs for the study of autistic spectrum disorder (ASD). In addition, we will give a broader perspective on the validity of this technology and to what extent it can be expected to complement animal models of ASD in the coming years.

KW - Induced pluripotent stem cells

KW - Autism

KW - SHANK3

KW - POSTSYNAPTIC DENSITY PROTEINS

KW - SINGLE POLYCISTRONIC VECTOR

KW - HUMAN IPS CELLS

KW - HUMAN KERATINOCYTES

KW - DELETION SYNDROME

KW - PURKINJE-CELLS

KW - SOMATIC-CELLS

KW - GENERATION

KW - DIFFERENTIATION

KW - EXPRESSION

U2 - 10.1007/s00213-013-3196-4

DO - 10.1007/s00213-013-3196-4

M3 - Article

SN - 0033-3158

VL - 231

SP - 1079

EP - 1088

JO - Psychopharmacology

JF - Psychopharmacology

IS - 6

ER -

The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

Abstract

Keywords

Access to Document

Fingerprint

Cite this